Global /China /Healthcare /Drug Manufacturers - General /301015
chevron_leftBack
Qingdao Baheal Medical INC. logo

Qingdao Baheal Medical INC.

301015
SHE: 301015 Delayed
24.65CNY -2.7%
3.65 USD
As of 18 June 2026, Qingdao Baheal Medical INC. has a market cap of $1.97B USD, ranking #7142 globally and #1753 in China. It ranks #574 in the Healthcare sector, and #226 in the Drug Manufacturers - General industry.
Global Rank
7142
Country Rank
1753
Sector Rank
574
Industry Rank
226
Key Stats
Market Cap
$1.97BUSD
13.32B CNY
Enterprise Value
$2.18BUSD
14.7B CNY
Revenue (TTM)
$1.1BUSD
7.45B CNY
EBITDA (TTM)
$132.07MUSD
892.45M CNY
Net Income (TTM)
$76.0MUSD
513.61M CNY
EBITDA Margin
12%
Profit Margin
6.9%
PE Ratio
26.4
Forward PE
14.8
PS Ratio
1.8
PB Ratio
4.6
EV/EBITDA
16.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Gang Fu open_in_new
Employees
3,064
Founded
2005
Website
baheal.cn open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-2.7% -1.7% 12% 8.3% -2.5% 43%

News

Loading...

Markets

Exchange Ticker Price
Shenzhen Stock Exchange
MIC: XSHE
PRIMARY
301015
青岛百洋医药股份有限公司 Class A
ISIN: CNE100004LR8
Shares Out.:
525.624M1 Shares Float: 452.36M2
TV:
SA:
YF:
GF:
BA:
MS:
24.65 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Qingdao Baheal Medical INC.

Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Harle, and Wei Xi Kang brand names. It also provides ophthalmic drugs under the HYCOSAN brand name; tumor and other severe drugs under the Human Albumin and Xospata brand names; anti-aging and cosmeceuticals under the Quanis, Excellula, TRANSINO, and Qingchunbao brand names; diabetes drugs under the Naida, Feburic, and Naite brand names; respiratory and anti-infective products under the Klacid brand name; and medical nutrition under the Nutrasumma brand name. The company was incorporated in 2005 and is based in Qingdao, China. Qingdao Baheal Medical INC. is a subsidiary of BAHEAL Pharmaceutical Holdings Limited.

Similar Companies

Industry: Drug Manufacturers - General (China)
Name
Market Cap diff.
PE
$53.99B
364.89B CNY
3K%
44.9
603259
$49.77B
336.36B CNY
2K%
17.2
$28.52B
223.48B HKD
1K%
35.7
$18.8B
147.32B HKD
854%
162.3
$16.56B
111.89B CNY
740%
-
9926
$16.01B
125.46B HKD
712%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
39K%
38.1
JNJ
$547.28B
28K%
26.4
ABBV
$360.63B
18K%
97.4
$323.08B
256.25B CHF
16K%
19.9
AZN
$289.5B
215.59B GBP
15K%
27.6
NOVN
$275.99B
218.9B CHF
14K%
20.5
chevron_leftBack